FMP
Financial data for every need
We provide one of the most accurate financial data available on the market. You can get historical prices, fundamental data, insider transactions, and much more that goes back 30 years in history.
Get started
70,000+ Stocks with tons of data
Ready to Unlock Insights?
Welcome to our comprehensive suite of tools designed to streamline your financial data integration process.
API Documentation
Access user-friendly RESTful API documentation suitable for all skill levels.
Detailed endpoint documentation.
Clear request/response examples.
Streamlined navigation.
Ensures clarity/reliability.
API Viewer
Explore endpoints hassle-free with our code-free API Playground.
Interactive data tools.
User-friendly interface.
Download data in CSV/Excel.
Ideal for hands-on exploration.
Stock Prices
Real-time Prices, Historical Data and Indicators.
Stock Fundamentals
Financial Statements, Key Metrics, Stock Financial Scores and more.
Market News
Stock News, Press Releases and Experts Articles.
Company Information
Company Outlook, Market Capitalization, Company Core Information.
Data is collected only from trusted sources
Quality data is key to making accurate, informed decisions. All our data is licensed and sourced from curated third-party data partners, such as the U.S. Securities and Exchange Commission (SEC), Board of Governors of the Federal Reserve System.
See DocumentationFast, accurate, and developer friendly
We provide one of the most accurate data available on the market. We spent years designing endpoints and made them informative, well-documented, and easy to use.
Our API has over 100 endpoints and we are still growing and adding new endpoints every week. Every endpoint is available in JSON format and most of them also in CSV format.
We also provide on demand custom endpoint available for our enterprise plan.
See documentationTrusted by 100,000+ customers
Join us and get your API key
Latest News
Stay Updated and Harness the Power of Our API with the Latest News!
Apr 4, 2025 7:59 PM - Davit Kirakosyan
Merit Medical Plunges 10% as China Tariffs Spotlight Exposure Risk
Shares of Merit Medical Systems (NASDAQ:MMSI) dropped over 10% intra-day today after China unveiled a 34% tariff on imported goods in response to the U.S. tariffs announced on April 2. While many medical device firms are expected to weather the impact relatively well due to limited cross-border trad...
Apr 4, 2025 7:56 PM - Davit Kirakosyan
Genuine Parts Gets an Upgrade: Resilient Business, Tariff Tailwinds, and Share Gain Potential
Evercore ISI upgraded Genuine Parts Company (NYSE:GPC) from In Line to Outperform, setting a new price target of $135, citing the stock's stability in a volatile market, potential tariff tailwinds, and promising cost-cutting initiatives. The firm sees Genuine Parts as one of the best-positioned name...
Apr 4, 2025 7:53 PM - Davit Kirakosyan
Johnson & Johnson Faces Pressure to Deliver After Talc Setback, But Long-Term Growth Still Intact
UBS reaffirmed its Buy rating on Johnson & Johnson (NYSE:JNJ) and maintained a $180 price target, but highlighted short-term volatility risks following the latest legal setback in the company’s ongoing talc litigation saga. A recent court decision marked the third rejection of J&J’s attempt to use b...
Apr 4, 2025 7:49 PM - Davit Kirakosyan
Verizon Ramps Up Consumer Focus with Price Lock and Free Phone Offers, UBS Stays Neutral
UBS is holding steady with its Neutral rating on Verizon Communications (NYSE:VZ) and maintains a $45 price target, following the telecom giant’s launch of two new customer-focused initiatives aimed at breathing life into its postpaid wireless business. Verizon unveiled a three-year price lock for b...
Apr 4, 2025 7:47 PM - Davit Kirakosyan
Citi Cuts Nordstrom to Sell: Limited Upside, Major Downside Risk Amid Deal Uncertainty
Citi downgraded Nordstrom (NYSE:JWN) from Neutral to Sell, citing an unfavorable risk/reward balance as shares hover near a potential buyout price but face sharp downside if the deal unravels. The firm also trimmed its price target to $22, down from $25. The downgrade stems from concerns around inve...
Apr 4, 2025 7:42 PM - Davit Kirakosyan
UBS Trims Neurocrine Price Target to $137, Still Sees Upside Amid Biotech Volatility
UBS maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but reduced its price target to $137 from $154, reflecting valuation adjustments in a turbulent biotech market. While trimming the target, UBS remains bullish on the company’s prospects. The firm views Neurocrine as a strong commerc...
Apr 4, 2025 1:00 PM - Stuart Mooney
APA Corporation's Director Buys Shares Amidst Stock Challenges
On April 3, 2025, Joung Chansoo, a director at NASDAQ:APA, purchased 75,000 shares of APA Corporation's Common Stock at $18.25 each. This acquisition increased his total holdings to 140,285 shares. APA Corporation is a U.S.-based oil and gas company involved in fracking, competing with firms like De...
